I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Ogama, Yoichiro
12
results:
Search for persons
X
Format
Online (12)
Mediatypes
Articles (Online) (8)
OpenAccess-fulltext (4)
Sorted by: Relevance
Sorted by: Year
?
1
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus..:
Haranaka, Miwa
;
Tanaka, Takanori
;
Kim, SungHyun
...
Immunotherapy. 15 (2023) 3 - p. 149-161 , 2023
Link:
https://doi.org/10.2217/..
?
2
Phase 1 Study to Investigate the Safety, Tolerability, and ..:
Noda, Naoto
;
Hamatani, Tatsuto
;
Shibue, Yuta
...
Clinical Pharmacology in Drug Development. 11 (2022) 10 - p. 1136-1146 , 2022
Link:
https://doi.org/10.1002/..
?
3
Phase 1 Clinical Trial of PPMX‐T003, a Novel Human Monoclon..:
Ogama, Yoichiro
;
Kumagai, Yuji
;
Komatsu, Norio
...
Clinical Pharmacology in Drug Development. 12 (2022) 6 - p. 579-587 , 2022
Link:
https://doi.org/10.1002/..
?
4
A randomized study to evaluate safety and immunogenicity of..:
Haranaka, Miwa
;
Baber, James
;
Ogama, Yoichiro
...
Nature Communications. 12 (2021) 1 - p. , 2021
Link:
https://doi.org/10.1038/..
?
5
Effects of a reactive oxygen species generator, napabucasin..:
Noda, Naoto
;
Takagaki, Takeshi
;
Yodo, Yasuhide
...
Pharmacology Research & Perspectives. 9 (2021) 5 - p. , 2021
Link:
https://doi.org/10.1002/..
?
6
A randomized dose-escalation study to assess the safety, to..:
Ogama, Yoichiro
;
Mineyama, Tomoko
;
Yamamoto, Asuka
...
International Journal of Hematology. 97 (2013) 3 - p. 351-359 , 2013
Link:
https://doi.org/10.1007/..
?
7
Effect of Milk on the Pharmacokinetics of Oseltamivir in He..:
Morimoto, Kaori
;
Kishimura, Kozue
;
Nagami, Takaaki
...
Journal of Pharmaceutical Sciences. 100 (2011) 9 - p. 3854-3861 , 2011
Link:
https://doi.org/10.1002/..
?
8
Loss or down‐regulation of HLA class I expression at the al..:
Masuda, Kozo
;
Hiraki, Akio
;
Fujii, Nobuharu
...
Cancer Science. 98 (2006) 1 - p. 102-108 , 2006
Link:
https://doi.org/10.1111/..
?
9
A randomized study to evaluate safety and immunogenicity of..:
Haranaka, Miwa
;
Baber, James
;
Ogama, Yoichiro
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671474/. , 2021
Link:
http://www.ncbi.nlm.nih...
?
10
Effects of a reactive oxygen species generator, napabucasin..:
Noda, Naoto
;
Takagaki, Takeshi
;
Yodo, Yasuhide
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502439/. , 2021
Link:
http://www.ncbi.nlm.nih...
?
11
A randomized study to evaluate safety and immunogenicity of..:
Miwa Haranaka
;
James Baber
;
Yoichiro Ogama
...
https://doi.org/10.1038/s41467-021-27316-2. , 2021
Link:
https://doi.org/10.1038/..
?
12
Effects of a reactive oxygen species generator, napabucasin..:
Naoto Noda
;
Takeshi Takagaki
;
Yasuhide Yodo
...
https://doi.org/10.1002/prp2.874. , 2021
Link:
https://doi.org/10.1002/..
1-12